Humana (HUM) brings KAH’s home sanitary unit under CenterWell

human inc. HUM recently completed the rebranding of the Kindred at Home (KAH) home healthcare unit into the CenterWell healthcare brand. The brand was launched by HUM last year to integrate three of its leading payer-independent health service offerings under one umbrella for better overall health outcomes.

Shares of Humana fell 0.5% on Sept. 2, replicating declines in broader markets.

After the transition, KAH’s home healthcare division is now officially known as CenterWell Home Health, which will target patients in more than 350 locations across 38 states. The transition of the home healthcare unit branding took place in three phases, with the first and second phases announced in March and June of this year. The latest announcement includes the rebranding of home health operations in 17 states, some of which are Alabama, Arkansas, California, Connecticut, Florida and Indiana.

The rebranding process of KAH’s home healthcare unit follows an integration of its home healthcare operations into Humana’s Home Solutions business. The latest move clearly reflects HUM’s efforts to advance its home health capabilities and increase its home solutions business, an integral part of its health services segment. The acquisition of KAH in 2021, which has remained the largest provider of home health and hospice services in the United States, also testifies to HUM’s continued efforts to strengthen its suite of home services.

Humana’s Home Solutions business will be well equipped to accelerate clinical innovation and launch a value-based operating model that transcends centuries-old clinical settings to deliver advanced healthcare services at affordable costs. All of this will be possible with the full integration of KAH’s home healthcare operations into the home solutions business.

The latest announcement also aims to introduce CenterWell, which is to integrate Humana’s primary care, pharmacy, and home healthcare offerings under one brand. Also noteworthy is the integration of services completed within a year and a half from the launch of the brand. The brand also appears to attract more customers as not only members of Humana’s health plan can access its services, but customers of various other health plans can also take advantage of the solutions.

After launching the brand in March 2021, Humana’s payer-oriented primary care facilities for the elderly were the first to switch to the new brand a month later. In June 2022, HUM completed the rebranding of its Humana Pharmacy and Humana Specialty Pharmacy pharmaceutical divisions into the CenterWell brand.

Humana shares gained 4.4% year to date compared to the industry rally of 3.4%.

Zacks investment research

Image source: Zacks Investment Research

Zacks rank and other key choices

Humana currently has a Zacks Rank # 2 (Buy). Some other top-tier titles in the medical space are The Ensign Group, Inc. ENSG, Senseonics Holdings, Inc. SENS and Health Services AMN, Inc. AMN. While AMN Healthcare currently sports a Zacks Rank # 1 (Strong Buy), Ensign Group and Senseonics currently have a Zacks Rank of 2. You can see The full list of Zacks # 1 Rank shares today here.

Ensign Group’s earnings topped estimates in three of the past four quarters and equaled the mark once, averaging 1.32%. The Zacks Consensus Estimate for ENSG’s 2022 earnings indicates an increase of 13.2%, while the same for revenues suggests a 13% improvement over their respective headcount a year ago. The consensus score for ENSG’s 2022 earnings has moved 0.5% north over the past 60 days.

Senseonics’ earnings topped estimates in three of the final four quarters and hit the once mark, with an average beat of 53.87%. The Zacks consensus estimate for SENS earnings in 2022 is pegged at 31 cents per share. A loss of 72 cents was reported the previous year. The same for revenues suggests growth of 15.4% compared to the previous year’s reading. The sign of consensus for SENS’s 2022 earnings has moved 416.7% north over the past 30 days.

AMN Healthcare’s bottom line surpassed estimates in each of the final four quarters, averaging 15.66%. The Zacks Consensus Estimate for AMN’s earnings for 2022 indicates a 40.2% increase, while the same for revenue suggests a 28.5% improvement over their respective headcount a year ago. The consensus sign for AMN’s 2022 earnings has moved 8.2% north over the past 30 days.

Shares of Ensign Group, Senseonics and AMN Healthcare have lost 1.8%, 19.1% and 17.4% respectively since the beginning of the year.

Want the latest advice from Zacks Investment Research? Today you can download 7 best actions for the next 30 days. Click to get this free report

Humana Inc. (HUM): Free Stock Analysis Report

AMN Healthcare Services Inc (AMN): Free stock analysis report

The Ensign Group, Inc. (ENSG): Free inventory analysis report

Senseonics Holdings, Inc. (SENS): Free stock analysis report

To read this article on click here.

Zacks investment research

Leave a Comment

Your email address will not be published.